MDWD MediWound Ltd. IFRS
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1593984 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-16.1%
TTM net income YoY21.0%
TTM EPS YoY30.7%
Revenue 3-yr CAGR-13.8%
Net income 3-yr CAGR—
Margins
Gross margin19.2%
Operating margin-149.0%
Net margin-140.8%
FCF margin-127.5%
EBITDA margin-145.5%
Returns
ROE-63.9%
ROA-29.9%
ROIC (approx.)-65.6%
Asset turnover0.21x
Leverage & solvency
Liabilities / assets49.4%
Debt / equity0.00x
Current ratio2.33x
Interest coverage-10.27x
Cash quality & payout
Operating cash flow / net income0.68x
Accruals ratio-9.7%
Payout ratio—
Capex / revenue32.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $16.96M | $20.22M | $18.69M | $26.50M | $23.76M |
| Cost of revenue | $13.71M | $17.59M | $15.11M | $13.33M | $14.99M |
| Gross profit | $3.25M | $2.63M | $3.58M | $13.16M | $8.77M |
| R&D expense | $14.32M | $8.88M | $7.47M | $10.18M | $10.26M |
| SG&A expense | $8.45M | $8.20M | $6.77M | $6.92M | $6.35M |
| Operating income | -$25.27M | -$19.40M | -$15.29M | -$8.35M | -$11.22M |
| Interest expense | $2.46M | $12.81M | $1.89M | $11.64M | $2.31M |
| Pretax income | -$23.71M | -$30.16M | -$6.53M | -$19.52M | -$13.52M |
| Income tax | $169,000 | $61,000 | $185,000 | $78,000 | $27,000 |
| Net income | -$23.88M | -$30.22M | -$6.72M | -$19.60M | -$13.55M |
| EBITDA | -$24.68M | -$18.77M | -$14.62M | -$7.92M | -$10.66M |
| EPS (basic) | -2.10 | -3.03 | -0.75 | -3.93 | -3.48 |
| EPS (diluted) | -2.10 | -3.03 | -0.75 | -3.93 | -3.48 |
| Weighted avg. shares (diluted) | 11.38M | 9.96M | 9.01M | 4.99M | 3.89M |
| Balance sheet | |||||
| Cash & equivalents | $4.80M | $9.15M | $11.87M | $33.90M | $11.05M |
| Short-term investments | $48.34M | $34.01M | $29.84M | $0 | $0 |
| Receivables | $1.62M | $4.80M | $3.70M | $9.33M | $1.78M |
| Inventory | $4.09M | $2.69M | $2.85M | $1.96M | $1.20M |
| Current assets | $59.96M | $52.16M | $49.70M | $45.84M | $14.95M |
| PP&E, netmay include right-of-use assets (IFRS) | $18.64M | $14.13M | $9.23M | $2.37M | $2.48M |
| Intangibles | $33,000 | $99,000 | $165,000 | $231,000 | $297,000 |
| Total assets | $86.25M | $73.50M | $66.46M | $50.02M | $19.74M |
| Current liabilities | $25.71M | $26.54M | $18.12M | $12.06M | $10.72M |
| Total liabilities | $42.62M | $42.34M | $34.86M | $39.10M | $24.33M |
| Shareholders' equity | $43.63M | $31.15M | $31.59M | $10.91M | -$4.58M |
| Shares outstanding | 12.84M | 10.79M | 9.22M | 7.24M | 3.90M |
| Cash flow statement | |||||
| Operating cash flow | -$16.12M | -$13.62M | -$10.46M | -$11.88M | -$8.92M |
| Capital expenditure | $5.50M | $6.27M | $6.46M | $555,000 | $489,000 |
| Free cash flow | -$21.63M | -$19.90M | -$16.93M | -$12.44M | -$9.40M |
| Investing cash flow | -$17.95M | -$8.40M | -$34.32M | -$481,000 | $3.55M |
| Financing cash flow | $29.62M | $19.39M | $22.92M | $35.76M | -$1.05M |
| Depreciation & amortization | $591,000 | $630,000 | $672,000 | $426,000 | $559,000 |
| Stock-based compensation | $3.11M | $3.14M | $1.94M | $1.95M | $1.67M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.